A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
Joerg Hasford(Ludwig-Maximilians-Universität München), Hassan Ansari(Zimmer Biomet (Netherlands)), Juan Luis Steegmann(Hospital Universitario de La Princesa), Michele Baccarani(University of Udine), Rüdiger Hehlmann(Heidelberg University), G. Alimena(Sapienza University of Rome), Markus Pfirrmann(Ludwig-Maximilians-Universität München), N. C. Allan(Western General Hospital)
Cited by 820
Related Papers
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
|Leukemia|2016|473
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464